

DAFTAR PUSTAKA

- Ahuja RB, Chatterjee P. 2014. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. *Burns*. 40:583-88.
- Akaishi S, Koike S, Dohi T. 2012. Nd:Yag Laser Treatment of Keloids and Hypertrophic Scars. *Eplasty*. 12:120-9.
- Al Attar A., Mess ST., Kauffman CL., Davison SP. 2006. Keloid pathogenesis and treatment. *Plast Reconstr Surg*. 117:286-300.
- Alster TS., Handrick C. 2000. Laser treatment of hypertrophic scars, keloids and striae. *Semin cutan med.*, 19:187-92.
- Andrews JP., Marttala J., Macarak E., Rosenblom J., Uitto J. 2016. Keloids: the paradigm of skin fibrosis-pathomechanisms and treatment. *Matrix Biol*, 51:37-46.
- Ardekani GS, Aghaei S, Nemati MH, Handjani F, Kasraee B. 2008. Treatment of a postburn keloid scar with topical captopril: report of the first case. *Plast Reconst Surg*. 123:123:112-3.
- Argirova M, Hadjiski O, Victorova A. 2006. Non-operative treatment of hypertrophic scars and keloids after burns in children. *Ann Burns and Fire Disasters*, 12:19-28.
- Arno AI., Gauglitz GG., Barret JP., Jeschke MG. 2015. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. *Burns*. 40:1255-66.
- Asawanonda P., Koo LS., Fitzpatrick TB., Taylor CR. 1999. UV-A1 for keloid. *Arch Dermatol*. 135: 348-9.
- Bond JE., Bergeron A., Thurlow P., Selim MA., Bowers EV., Kuang A. 2011. Angiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progression. *Mol Med*. 17:1196-203.
- Butler PD, Longaker MT, Yang GP. 2008. Current progress in keloid research and treatment. *J Am Coll Surg*. 206:731-41.
- Bailey J, Waite A, Clayton W, Rustin M. 2007. Application of topical mitomycin C to the base of shave-removed keloid scars to prevent their recurrence. *Br J Dermatol*. 156:682-6.
- Berman B, Maderal A, Raphael B. 2016. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. *Dermatol Surg*. 106:608-12.

- Biljard E, Steltenpool S., Niessen FB. 2015. Intralesional 5-fluorouracil in keloid treatment: a systematic review. *Acta Derm Venereol.* 95:778-82
- Boggio RF, Boggio LF, Galvao BL, Machado-Santelli GM. 2014. Topical verapamil as a scar modulator. *Aesthetic Plat Surg.* 3:968-75.
- Broadway D, Grierson I, O'Brien C, Hitchings RA. 1993. The effect of topical antiglaucoma medication on the conjunctival cell profile and the result of trabeculectomy. *Invest Ophthalmol Vis Sci.* 34:724.
- Caroll LA., Hanasono MM., Mikulec AA., Kita M., Koch RJ. 2002. Triamcinolone stimulates bFGF production and inhibits TGF-beta1 production by human dermal fibroblasts. *Dermatol Surg.* 28:704-9.
- Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. 2012. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. *Ophthal Plast Reconstr Surg.* 28:103-6.
- Chen J, Zhao S, Liu Y, Cen Y, Nicolas C., 2016. Effect of captopril on collobat metabolisms in keloid fibroblast cells. *ANZ J Surg.* 86:1046-51.
- Clark JA, Turner ML., Howard L., Stanescu H., Kleta R., Kopp JB. 2009. Description of familial keloids in five pedigrees: evidence for autosomal dominant inheritance and phenotypic heterogeneity. *BMC Dermatol.* 28:1471-9.
- Copcu E, Sivioglu N, Oztan Y. 2004. Combination of surgery and intralesional verapamil injection in the treatment of the keloid. *J Burn Care Rehabil.* 2004:1-7.
- Cunliffe I., McIntyre C., Rees R., Rennie I. 1995. The effect of topical beta-blocker medications on the proliferation and viability of human Tenon's capsule fibroblasts in tissue culture. *Ger J Ophthalmol.* 4:167-74.
- Danarti R, Ariwibowo L, Radiono S, Budiyo A. 2016. Topical Timolol Maleate 0,5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A single- Center Experience of 278 cases. *Dermatology.* 2016; 232:566-71.
- Darougheh A, Asilian A, Shariati F. 2009. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *Clinical and Experimental Dermatology.* 34:219-23.
- Dong X., Zhang C., Ma S., Wen H. 2014. Mast cell chymase in keloid induces profibrotic response via transforming growth factor- β 1/Smad activation in keloid fibroblasts. *Int J Clin Exp Pathol.* 157:3596-7.
- Enoshiri T, Naitoh M., Yamawaki S, Kawaguchi A., Aya R., Noda ., dkk. 2017. β -adrenergic receptor blockers reduce the occurrence of keloids and hypertrophic

- scars after cardiac device implantation: a single-institution case-control study. *Plast Reconstr Surg.*, 13:1248-56.
- Falanga V., Iwamoto S. 2012. Mechanisms of wound repair, wound healing, and wound dressing. *Fitzpatrick's Dermatology in General Medicine 8th*. p 2984-96.
- Fujiwara M., Muragaki Y., Ooshima A. 2005. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depends on matrix metalloproteinase for migration. *Br J Dermatol.* 153:295-300.
- Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. 2011. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. *Mol Med.* 17:113-25.
- Gauglitz GG, 2013. Management of keloids and hypertrophic scars: current and emerging options. *Clin Cosmet Investig Dermatol.* 6:103-14.
- Gold MH., McGuire M., Mustoe TA., Pusic A., Sachev M., Waibei J. 2014. Updated international clinical recommendations on scar management: part 2-algorithms for scar prevention and treatment. *Dermatol Surg.* 40:825-31.
- Hamrick M., Boswell W., Carney D. 2009. Successful treatment of earlobe keloids in the pediatric population. *J Pediatr Surg.* 44:286-8.
- Har-Shai T, Amar M, Sabo E. 2003. Intralesional cryotherapy for enhancing the involution of hypertrophic sars and keloids. *Plast Reconstr Surg.* 111:1841-52.
- Hochman B., Isoldi FC., Furtado F., Ferreira LM. 2015. New approach to the understanding of keloid: psychoneuroimmune-endocrine aspects. *Clin Cosmet Investig Dermatol.* 8:67-73.
- Hosnuter M., Payasli C., Isikdemir A., Terkoglu B. 2007. The effects of onion extract on hypertrophic and keloid scars. *J Wound Care.* 16:251-4.
- Ianello S, Milazzo, Bordonaro F, Belfiore F. 2006. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid-two case reports and literature review. *MedGenMed.* 8:60
- Jagadeesan J., Bayat A. 2007. Transforming growth factor beta and keloid disease. *IJS.* 5:278-85.
- Jones CD, Guiot L, Samy M, Gorman M, Tehrani H, 2015. The use of chemotherapeutics for the treatment of keloid scars. *Derm reports,* 7:5880.
- Ji Y, Chen S., Li K., Xiao X., Zheng S., Xu T. 2013. The role of B-adrenergic receptor signaling in the proliferation of hemangioma-dervied endothelial cells. *Cell Div.* 8:1.

- Juckett G, Adams HH, 2009. Management of Keloids and Hypertrophic scars. *Am Fam Physician*. 80:253-60.
- Kawaguchi Y, Kamatani N. 2002. Contribution of angiotensin II type I and type II receptors (AT-1 and AT-2) collobat synthesis by skin fibroblasts.*Nihon rinsho*. 60:1940-4.
- Khan MA., Bashir MM., Khan FA. 2014. Intralesional triamcinolone alone and in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. *J Pak Med Assoc*.64:1003-7.
- Kelly AP. 2009. Update on the management of keloids. *Semin Cutan Med Surg*.,28:71-6.
- Köse O., Waseem A. 2008. Keloids and hypertrophic scars: are they two different sides of the same coin? *Dermatol Surg*.,34:336-46.
- Kho CJ, 2012. Dermal Hypertrophies and Benign Fibroblastic/Myofibroblastic Tumors. *Fitzpatrick's Dermatology in General Medicine 8th*. p. 707-11.
- Krakowski AC, Totri CR, Donelan MB. 2016. Scar management in the Pediatrics and Adolescent Populations. *Pediatrics*, 137: 1-17.
- Love PB., Kundu RV. 2013. Keloids: an update on medical and surgical treatments.*J Drugs Dermatol*.12:403-9.
- Li Zhouna., Jin Zhehu. 2016. Comparative effect and safety of verapamil in keloid and hypertrophic scar treatment: a meta-analysis. *TCRM*. 12:1635-41.
- Manuskiatti W., Fitzpatrick RE. 2002. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585 nm flashlamp-pumped pulsed-dye laser treatments. *Arch Dermatol*. 138:1149-55.
- Mamalis AD., Lev-Toh H., Nguyen DH., Jadgeo JR. 2014. Laser and light-based treatment of keloids - a review. *J Eur Acad Dermatol Venereol*. 28:689-99.
- Mari W., Alsabri SG., Tabal N., Younes S., Sherif A., Simman R. 2016. Novel insights on understanding of keloid scar: article review. *JCCW*. 7, 1-7.
- Martine F., Raphael JM., Johannes MPJ., Florian A., Niels JE., Yves TB. 2016. Traetment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature. *Expert Opin Drug Saf*. 15:199-214.
- Mesquita CJ. 2010. About strawberry, crab claws, and the Sir James Black's invention. Hypothesis: can we battle keloids with propranolol. *Med Hypotheses*, 74(2):353-9.
- Moehrle M, Léauté-Labrèze C, Schmidt V, Röcken M, Poets CF, Goelz R. 2013.

- Topical timolol for small hemangiomas of infancy. *Pediatric Dermatology*, 30:245-9.
- Molinari BL., Tasar DR., Palmieri MA., O'Connor SE., Cabrini RL. 2003. Cell-based quantitative evaluation of the MTT assay. *Anal Quant Cytol Histol*. 25:254-62.
- Nedelec B, De Oliveira A, Saint-Cyr M, Garrel DR. 2007. Differential effect of burn injury on fibroblasts from wounds and normal skin. *Plast Reconstr Surg*. 119:2101-9.
- Nickenig G., Geisen G., Vetter H., Sachidinis A. 1997. Characterization of angiotensin receptors on human skin fibroblasts. *J Mol Med*. 75:217-22.
- Norman NS., Lotti VJ., Gautheron P., Schmitt C., Gross D., dkk., 1984. R-enantiomer of timolol: a potential selective ocular antihypertensive obatt. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 221: 234-8.
- Ogawa R. 2010. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. *Plast and Recons Surg*. 125:557-68.
- Ogawa R., Akaishi S., Huang C., Dohi T., Aoki M., Omori Y., dkk. 2011. Clinical application of basic research that shows reducing skin tension could prevent and treat abnormal scarring: The importance of facial/subcutaneous tensile reduction sutures and flap surgery for keloid and hypertrophic scar reconstruction. *J Nippon Med*. 78:68-76.
- Painter SL., Hildebrand GD. 2016. Topical timolol maleate 0.5% solution for the management of deep periocular infantile hemangiomas. *J AAPOS*. 20:172-4.
- Park SK, Choi YS, Kim HJ, 2013. Hypopigmentation and subcutaneous fat, muscle atrophy after local corticosteroid injection. *Korean J Anesthesiol*. 65:S59-61.
- Pope E, Chakkittakandiyil A. 2010. Topical timolol gel for infantile hemangiomas: A pilot study. *Arch Dermatol*. 146:564-5.
- Prakash NS., Malikarjunappa AM., Pulkit A. 2013. Effect of mitomycin c application on head and neck keloids. *J.J.M. Medical College*. pp 58-60.
- Reddy R., Harinatha S., Raghunath. 2015. The role of bleomycin in management of hypertrophic scars and keloids - a clinical trial. *Our dermatol online*. 6: 404-6.
- Robles DT., Berg D. 2007. Abnormal wound healing. *Clin Dermatol*, 25:26-32.
- Roques C., Téot L. 2008. The use of corticosteroids to treat keloids: a review. *Int J Low Extrem Wounds*. 7:137-45.
- Salem A, Assaf M., Helmy A., Nofal A., Ibrahim S., Eldeeb F., dkk. , 2009. Role of vascular endothelial growth factor in keloids: a clinicopathologic study. *Int*

J Dermatol., 48:1071-7.

- Saray Y., Güleç AT. 2015. Treatment of keloids and hypertrophic scars with dermohet injections of bleomycin: a preliminary study. *Int J Dermatol*, 44:777-84.
- Schneider M., Meites E., Daane SP. 2013. Keloids: which treatment is best for your patient? *J Fam Pract.* p227-9.
- Shah VV., Aldahan AS,m Nouri K. 2016. 5- Fluroruracil in the treatment of keloids and hypertrophic scars: a comprehensive review of the literature.*Dermatol Ther.*6:169-83.
- Shanti M, Dhanraj P. 2007. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. *Indian J Dermatol Venereol Leprol.*74:343-8.
- Sharma S, Bassi R, Gupta A. 2012. Treatment of small keloids with intralesional 5-fluorouracil alone vs intralesional triamcinolone aetonide sith 5-fluorouracil. *J Pak Assoc Dermatol.* 22:35-40.
- Sidgwick GP., McGeorge D, Bayat A. 2015.A comprehensive evidence based review on the role of topicals and dressings in the management of skin scarring. *Arch Dermatol Res.*307:461-77.
- Son D, Harijan A. 2014. Overview of surgical scar prevention and management. *J Korean Med Sci.* 29:751-7
- Tuan TL, Nichter LS. 1998. The molecular basis of keloid and hypertrophic formation. *Mol Med Today.* 25:224-32.
- Viera MH, Amini S, VAlins W, Berman B. 2010. Innovative therapies in the treatment of keloids and hypertrophic scars. *J Clin Aesthetic Dermatol.* 3:20-6.
- Wang R, Mao Y, Zhang Z, Li Z, Chen J, Chen Y. 2015. Role of verapamil in preventing and treating hypertrophic scars and keloids. *Int Wound J.* 35:90-9.
- Williams DE., Nguyen KD., Tehrani SS., Kitada S., Lee DA. 1992. Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture. *Invest Ophthalmol Vis Sci.* 22:2233-41.
- Wilson AM. 2013. Eradication of keloids: surgical excision followed by a single injection of intralesional 5-fluorouracil and botulinum toxin. *Can J Plast Surg.*21:87-91
- Wolfram D, Tzankov A, Pülzl P, Piza KH. 2009. Hypertrophic scars and keloids- a review of their patophysiology, risk factors, and therapeutis management., *Dermatol Surg.* 35(2): 171-81.

- Wu Ky., Wu CP., Lai YH., Hong SJ. 2013. Novel usage of intraocular pressure-lowering drugs as wound-healing inhibitors after trabeculectomy with cell culture and animal models. *KJMS*.29:353-61.
- Yamamoto T. 2006. Bleomycin and the skin. *Br J Dermatol*. 155:869-75.
- Yang Jy, Huang Cy. 2010. The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars. *Dermatol Surg*. 36:1942-9.
- Yu L, Li S, Su B, Liu Z, Fang J, Zhu L, dkk. 2013. Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants. *Exp Ther Med*. 6:388-90.
- Zhang Z. Nie F., Kang C., Chen B., Qin Z., Ma J. dkk. 2014. Increased periostin expression affects the proliferation, collagen synthesis, migration and invasion of keloid fibroblasts under hypoxic conditions. *Int J Mol Med*. 11:253-61.
- Zhibo X., Miaobo Z. 2009. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. *Plast Reconstr Surg*.125:1573-4.